BridgeBio Pharma (BBIO) Other Working Capital Changes (2018 - 2026)

BridgeBio Pharma has disclosed Other Working Capital Changes across 9 years of filings, most recently posting -$2.4 million for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$2.4 million, up 7.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.2 million (down 138.05% YoY), and the FY2025 annual result was -$11.4 million, down 152.24% from the prior year.
• Other Working Capital Changes came in at -$2.4 million for Q1 2026 at BridgeBio Pharma, up from -$6.7 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $26.3 million in Q4 2024 to a low of -$27.0 million in Q2 2024.
• The 5-year median for Other Working Capital Changes is -$1.8 million (2022), against an average of $266176.5.
• Peak annual rise in Other Working Capital Changes reached 578.26% in 2024, while the deepest fall reached 351.21% in 2024.
• BridgeBio Pharma's Other Working Capital Changes stood at $3.8 million in 2022, then soared by 86.13% to $7.2 million in 2023, then jumped by 267.49% to $26.3 million in 2024, then plunged by 125.33% to -$6.7 million in 2025, then jumped by 64.34% to -$2.4 million in 2026.
• The last three Other Working Capital Changes figures came in at -$2.4 million (Q1 2026), -$6.7 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.